May 2015/ Jinan University, etc./ International Journal of Oncology
Compilation / 우팅야오
The resistance of cancer cells to multiple chemotherapeutic drugs makes cancer treatment difficult. One of the key reasons why cancer cells develop multi-drug resistance is that the protein ABCB1 (ATP-binding cassette sub-family B member 1) on the cell surface will expel drugs out of the cell, causing insufficient drug concentration in cells to kill cancer cells.
According to research published by Jinan University and others, a single triterpenoid “ganoderenic acid B” isolated from영지버섯 can regulate the gene of drug resistance protein ABCB1, reduce its expression level, and at the same time inhibit the activity of ABCB1 ATPase, preventing ABCB1 from performing its function of “expelling chemotherapeutics out of the cell.”
By cultivating ganoderenic acid B and the drug-resistant liver cancer cell line HepG2/ADM together, the chemotherapeutic drug (rhodamine-123) that was originally blocked can enter the cancer cells and accumulate a considerable amount there. Ganoderenic acid B can indeed help increase the toxic effect of doxorubicin, vincristine and paclitaxel against the drug-resistant HepG2/ADM and even improve the therapeutic effect of doxorubicin against drug-resistant breast cancer cell line MCF-7/ADR.
과거에, studies in Taiwan have confirmed through cell and animal experiments that the ethanol extract of Ganoderma tsugae (triterpenoid total extract) can improve the therapeutic effect of chemotherapeutic drugs against drug-resistant lung cancer cells (Evid. Based compiement alternat Med. 2012; 2012:371286 ). Now the experiment of Jinan University clearly pointed out that the ganoderenic acid B in the triterpenoids is the active ingredient to reverse drug resistance of cancer cells. The connection of these different experiments has made the function of 영지버섯 triterpenoids in reversing the drug resistance of cancer cells increasingly obvious.
The development of inhibitors against drug-resistant proteins such as ABCB1 is currently the goal of the active efforts of the medical community, but it seems that there is no ideal drug yet (Taiwan Medical Community, 2014, 57: 15-20). Preliminary research results have pointed out the potential of ganoderenic acid B in this area, and we look forward to further animal experiments to provide stronger evidence in the future.
[원천] Liu DL, 외. Ganoderma lucidu derived ganoderenic acid B reverses ABCB1-mediated multidrug resistance in HepG2/ADM cells. Int J Oncol. 46(5):2029-38. 도이: 10.3892/ijo.2015.2925.
END
저자 소개 / 씨. 우팅야오
Wu Tingyao가 직접 보고해 왔습니다. Lingzhi 이후의 정보 1999. 그녀는 다음의 저자입니다. Ganoderma로 치유 (4월 인민의학출판사에 게재 2017).
★ 이 글은 저자의 단독 승인 하에 게재되었습니다.
★ 위 작품은 복제할 수 없습니다, 저작자의 허락 없이 발췌하거나 다른 방법으로 사용한 경우
★ 위의 내용을 위반한 경우, 저자는 관련 법적 책임을 추구할 것입니다.
★ 이 기사의 원문은 Wu Tingyao가 중국어로 작성하고 Alfred Liu가 영어로 번역했습니다.. 번역 내용에 차이가 있는 경우 (영어) 그리고 원본 (중국인), 원래 중국어가 우선합니다. 독자들이 궁금한 점이 있으면, 원작자에게 연락주세요, 양. 우팅야오.
